Healthcare -
Biotechnology - NASDAQ - US
$ 41.96
1.89 %
$ 2.5 B
Market Cap
-11.62
P/E
1. INTRINSIC VALUE
Balance Sheet
Apogee Therapeutics, Inc.
| Current Assets | 530 M |
| Cash & Short-Term Investments | 521 M |
| Receivables | 4.7 M |
| Other Current Assets | 4.36 M |
| Non-Current Assets | 224 M |
| Long-Term Investments | 210 M |
| PP&E | 13.3 M |
| Other Non-Current Assets | 498 K |
| Current Liabilities | 28.6 M |
| Accounts Payable | 1.07 M |
| Short-Term Debt | 3.23 M |
| Other Current Liabilities | 24.3 M |
| Non-Current Liabilities | 8.6 M |
| Long-Term Debt | 8.6 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Apogee Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 217 M |
| Operating Income | -217 M |
| Other Expenses | -34.7 M |
| Net Income | -182 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Apogee Therapeutics, Inc.
| Net Income | -182 M |
| Depreciation & Amortization | 189 K |
| Capital Expenditures | -1.15 M |
| Stock-Based Compensation | 23.3 M |
| Change in Working Capital | -2 M |
| Others | -11.5 M |
| Free Cash Flow | -172 M |
Wall Street Analysts Price Targets
Apogee Therapeutics, Inc.
APGE has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
APGE does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Apogee Therapeutics, Inc.
Sold
0-3 MONTHS
198 K USD 1
3-6 MONTHS
2.17 M USD 2
6-9 MONTHS
5.13 M USD 2
9-12 MONTHS
4.43 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
991 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 129.1% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
zacks.com
- 3 weeks ago
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
SAN FRANCISCO and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 10:30 a.m. E.T.
globenewswire.com
- 1 month ago
Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet
The consensus price target hints at a 132.7% upside potential for Apogee Therapeutics Inc. (APGE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
zacks.com
- 1 month ago
Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class
Apogee Therapeutics, Inc. achieved positive interim results from phase 1b study using APG808 for the treatment of patients with Asthma. Interim 16-week data from the phase 2 APEX study using APG777 for the treatment of patients with AD expected mid-2025. The global asthma treatment market size is projected to reach $35.93 billion by 2034.
seekingalpha.com
- 1 month ago
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling
globenewswire.com
- 1 month ago
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53%
globenewswire.com
- 1 month ago
Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade
The mean of analysts' price targets for Apogee Therapeutics Inc. (APGE) points to a 134% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
zacks.com
- 2 months ago
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
SAN FRANCISCO and BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will present at the Bank of America Health Care Conference on Tuesday, May 13, 2025, at 1:40 p.m. P.T. / 4:40 p.m. E.T.
globenewswire.com
- 2 months ago
Apogee Therapeutics: Engineering Biologic Dominance
Apogee's strong financial position, with $731.1 million in cash, funds operations through Q1 2028, de-risking its ambitious pipeline development in inflammatory diseases. Significant R&D investments in lead IL-13 inhibitor APG777 and combination therapies reflect a strategic push for differentiated, best-in-class treatments in atopic dermatitis and asthma. Encouraging Phase 1 data for OX40L inhibitor APG990 supports its combination potential with APG777, promising infrequent dosing and broad efficacy in inflammatory diseases.
seekingalpha.com
- 2 months ago
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial
On Monday, Apogee Therapeutics, Inc. APGE released interim Phase 1 results from its first-in-human trial of APG990.
benzinga.com
- 4 months ago
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results
Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025
globenewswire.com
- 4 months ago
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody, exceeded trial objectives and demonstrated an approximately 60-day half-life
globenewswire.com
- 4 months ago
8. Profile
Summary
Apogee Therapeutics, Inc. APGE
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 2.5 B
Dividend Yield
0.00%
Description
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Contact
221 Crescent Street, Waltham, MA, 02453
https://www.apogeetherapeutics.com
IPO
Date
July 14, 2023
Employees
196
Officers
Dr. Drew Badger Ph.D.
Senior Vice President and Head of Regulatory Affairs & Toxicology
Ms. Emily Cox
SVice President & Head of People
Ms. Wendy Aspden-Curran
Senior Vice President of Clinical Operations
Dr. Michael Thomas Henderson M.D.
Chief Executive Officer & Director
Ms. Jane Pritchett V. Henderson
Chief Financial Officer
Ms. Noel Kurdi
Vice President of Investor Relations
Ms. Monica Forbes
Senior Vice President of Finance
Dr. Carl Linden Dambkowski M.D.
Chief Medical Officer
Mr. Matthew Batters J.D.
Chief Legal Officer & Corporate Secretary
Dr. Rebecca Dabora Ph.D.
Chief Development Officer